Teva Pharmaceutical’s U.S. Unit Indicted on Price-Fixing Charges

WASHINGTON—The U.S. business of Teva Pharmaceutical Industries Ltd. was indicted Tuesday on charges the generic drugmaker fixed prices on cholesterol medication and other drugs.

The Justice Department’s antitrust division brought the case in a Pennsylvania federal court, alleging Teva Pharmaceuticals USA engaged in anticompetitive conduct that resulted in at least $350 million in overcharges to consumers.


Read More

READ MORE:   Apple fined record $1.2B in France over anti-competitive sales practices

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button